Email this article 
Immunohistochemical analysis of molecular cell structures of genetic and adaptive immunityin patients suffering from psoriasis in the course of biological therapy
- Authors: Katunina OR1, KATUNINA OR1
-
Affiliations:
- Issue: Vol 87, No 5 (2011)
- Pages: 70-77
- Section: Articles
- Submitted: 11.03.2020
- Published: 15.10.2011
- URL: https://vestnikdv.ru/jour/article/view/1067
- DOI: https://doi.org/10.25208/vdv1067
- ID: 1067
Cite item
Full Text
Abstract
The author used the immunohistochemical method to study an effect of the biological modifier of immune reactions of
Infliximab on immunopathogenetic mechanisms directly in the affected skin of patients suffering from psoriasis.
Infliximab on immunopathogenetic mechanisms directly in the affected skin of patients suffering from psoriasis.
References
- Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
- Gudjonsson J.E. Psoriasis: epidemiology. Clin. Dermatol 2007; 25:6: 535-546.
- Lowes M.A. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 22: 866-872.
- Gudjonsson J.E., Elder J.T. "Psoriasis." In: Wolff. K, Goldsmith L.A., Katz S.I. et al. (editors) Fitzpatrick's Dermatology in General Medicine. 7th ed. New York: McGraw Hill Medical; 2008. p. 169-93.
- Клиническая дерматовенерология / Под ред. Ю.К. Скрипкина, Ю.С. Бутова. М.: ГЭОТАР- Медиа 2009; II: 8: 212-33.
- Navarini A.A. Psoriasis. Therapeutische Umschau 2010; 67: 4: 153-165.
- Braun J. Owerview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert. Opin Biol Ther 2003; 3: 1: 141-168.
- Gottlieb A.B. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled triаl. J Am Acad Dermatol 2004; 51: 4: 534-542.
- Кубанов А.А. Опыт применения препарата инфликсимаб в лечении больных псориазом тяжелого течения. Вестн. дерматол. и венерол., 2008; 6: 81-86.
- Курдина М.И. Клинико-иммунологические параллели у больных псориазом на фоне лечения инфликсимабом. Клин. дерматол. и венерол., 2010; 2: 77-80.
- Симбирцев А.С. Толл-белки: специфические рецепторы неспецифического иммунитета. Иммунология, 2005; 6: 368-377.
- Vincek V. Infliximab monotherapy in psoriasis: A case of rapid clinical and histological response. Intern J of Dermatol 2004; 43: 303-308.
- Goedkoop А.Y. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004; 6: 326-334.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).